BioNTech SE Sponsored ADR $BNTX Stock Position Increased by Candriam S.C.A.

Candriam S.C.A. increased its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 4.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 520,972 shares of the company’s stock after purchasing an additional 23,442 shares during the period. Candriam S.C.A. owned 0.21% of BioNTech worth $51,399,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BNTX. Flossbach Von Storch SE purchased a new position in BioNTech during the 2nd quarter worth approximately $207,142,000. Bank of America Corp DE increased its position in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after buying an additional 166,432 shares during the period. First Trust Advisors LP increased its position in BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after buying an additional 451,124 shares during the period. Assenagon Asset Management S.A. lifted its stake in BioNTech by 79.7% in the third quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after buying an additional 337,412 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in BioNTech by 11.2% in the third quarter. Pictet Asset Management Holding SA now owns 206,580 shares of the company’s stock valued at $20,363,000 after buying an additional 20,777 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other BioNTech news, CEO Ugur Sahin sold 36,209 shares of the stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the completion of the sale, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 807,209 shares of company stock worth $79,246,837. 19.20% of the stock is owned by corporate insiders.

BioNTech Stock Performance

NASDAQ BNTX opened at $87.51 on Friday. The company has a quick ratio of 7.80, a current ratio of 8.55 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The business’s 50-day moving average price is $94.66 and its 200 day moving average price is $96.70. The firm has a market cap of $22.13 billion, a P/E ratio of -12.78 and a beta of 1.28.

Wall Street Analyst Weigh In

BNTX has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday. UBS Group cut their target price on shares of BioNTech from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday. Canaccord Genuity Group reduced their price target on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research report on Wednesday, October 14th. Finally, Citigroup reduced their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $123.60.

BioNTech Company Profile

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases.

The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio.

BioNTech works with partners to develop and distribute products internationally.